Dare Bioscience vs 60 Degrees Pharmaceuticals
DARE and SXTP side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How DARE and SXTP compare
Dare Bioscience is the larger company, worth 5.5 times as much as 60 Degrees Pharmaceuticals ($10.1M against $1.8M).
60 Degrees Pharmaceuticals keeps more of each dollar of sales as profit, with a net margin of −730% compared with −804% at Dare Bioscience.
60 Degrees Pharmaceuticals scores higher on the StockData Score (8 against 5 for Dare Bioscience), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | DARE | SXTP |
|---|---|---|
| Size and price | ||
| Market cap | $10.1M | $1.8M |
| Share price | $0.657 | $0.518 |
| Change, 1 year | −66.8% | −89.5% |
| Change, 5 years | −96.7% | – |
| Beta (5Y) | 1.40 | 2.09 |
| Employees | 24 | 3 |
| StockData Score | ||
| Total score | 5 | 8 (better) |
| Valuation score | 0 | 3 (better) |
| Growth score | 0 | 2 (better) |
| Performance score | 1 | 1 |
| Health score | 4 (better) | 2 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 7.4× | 1.6× (better) |
| P/B | – | 0.7× |
| FCF yield | −117% (better) | −488% |
| Fair value | – | $1.29 |
| Margin of safety | – | 59.7% |
| Growth | ||
| Revenue growth (TTM) | – | 73.2% |
| Profitability | ||
| Gross margin | – | 19.4% |
| Operating margin | −813% | −775% (better) |
| Net margin | −804% | −730% (better) |
| FCF margin | −861% | −801% (better) |
| Return on equity | – | −322% |
| Return on invested capital | – | −659% |
| Financial health | ||
| Debt / equity | – | 0.00 |
| Interest coverage | – | −1134.8× |
| Current ratio | 0.99 | 2.32 (better) |
| Altman Z-score | −13.51 (better) | −22.23 |
| Piotroski F-score | 4 (better) | 2 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 8.5% | 21.5% |
| Held by insiders | 9.4% | 21.0% |
| Insider net buying, 12 months | – | $30.1K |
| Short interest, % of float | 7.1% | – |
Go deeper
- DARE stock overview
- DARE income statement
- DARE valuation and score
- SXTP stock overview
- SXTP income statement
- SXTP valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.